skip to content
Risk-Benefit Analysis in Drug Research : Proceedings of an International Symposium held at the University of Kent at Canterbury, England, 27 March 1980 Preview this item
ClosePreview this item
Checking...

Risk-Benefit Analysis in Drug Research : Proceedings of an International Symposium held at the University of Kent at Canterbury, England, 27 March 1980

Author: J F Cavalla
Publisher: Dordrecht : Springer Netherlands : Imprint : Springer, 1981.
Edition/Format:   eBook : Bibliographic data : EnglishView all editions and formats
Summary:
The appreciation of risk like the awareness of beauty lies very much in the eyes of the beholder. It involves a value judgement and can never be absolute. Yet paradoxically, modern society is demanding ever greater degrees of safety in the medicines it takes, to the extent that nothing short of the total absence of risk will be tolerated. Since 1960, and mainly as a result of the thalidomide tragedy, governmental  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

Find a copy online

Links to this item

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Genre/Form: Electronic books
Additional Physical Format: Printed edition:
Material Type: Bibliographic data, Internet resource
Document Type: Internet Resource, Computer File
All Authors / Contributors: J F Cavalla
ISBN: 9789401571326 9401571325 9789401571340 9401571341
OCLC Number: 840311790
Language Note: English.
Description: 1 online resource (197 pages)
Contents: 1 Risk --
benefit in medicine --
2 The effect on industry --
3 The effect on the public --
Discussion of Chapters 2 and 3 --
4 The necessary role of government --
5 Problems facing a regulatory authority --
Discussion of Chapters 4 and 5 --
6 The effect on pharmaceutical research --
7 New-drug assessment in man: a clinical pharmacologist's view --
Discussion of Chapters 6 and 7 --
8 The effect on choice of research --
9 The relative worth of animal testing --
10 The prospect of product liability --
Discussion of Chapters 9 and 10 --
11 The effect on world medicine --
12 Preclinical requirements --
13 Post-marketing drug surveillance --
Discussion of Chapters 12 and 13 --
14 The influence of the media --
Discussion of Chapter 14 --
15 The influence of the medical profession --
Summary and conclusions.
Responsibility: edited by J.F. Cavalla.

Abstract:

Since 1960, and mainly as a result of the thalidomide tragedy, governmental regulation of testing and use of new medicines has grown apace throughout the world. Both these concerns have been inflamed  Read more...

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.

Similar Items

Related Subjects:(2)

Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


Primary Entity

<http://www.worldcat.org/oclc/840311790> # Risk-Benefit Analysis in Drug Research : Proceedings of an International Symposium held at the University of Kent at Canterbury, England, 27 March 1980
    a schema:CreativeWork, schema:Book ;
   library:oclcnum "840311790" ;
   library:placeOfPublication <http://experiment.worldcat.org/entity/work/data/836679407#Place/dordrecht> ; # Dordrecht
   library:placeOfPublication <http://id.loc.gov/vocabulary/countries/ne> ;
   rdfs:comment "Unknown 'gen' value: bdt" ;
   schema:about <http://id.worldcat.org/fast/1014893> ; # Medicine
   schema:about <http://id.worldcat.org/fast/1153364> ; # Toxicology
   schema:about <http://dewey.info/class/615/e23/> ;
   schema:bookFormat schema:EBook ;
   schema:creator <http://viaf.org/viaf/45641901> ; # J. F. Cavalla
   schema:datePublished "1981" ;
   schema:description "1 Risk -- benefit in medicine -- 2 The effect on industry -- 3 The effect on the public -- Discussion of Chapters 2 and 3 -- 4 The necessary role of government -- 5 Problems facing a regulatory authority -- Discussion of Chapters 4 and 5 -- 6 The effect on pharmaceutical research -- 7 New-drug assessment in man: a clinical pharmacologist's view -- Discussion of Chapters 6 and 7 -- 8 The effect on choice of research -- 9 The relative worth of animal testing -- 10 The prospect of product liability -- Discussion of Chapters 9 and 10 -- 11 The effect on world medicine -- 12 Preclinical requirements -- 13 Post-marketing drug surveillance -- Discussion of Chapters 12 and 13 -- 14 The influence of the media -- Discussion of Chapter 14 -- 15 The influence of the medical profession -- Summary and conclusions."@en ;
   schema:description "The appreciation of risk like the awareness of beauty lies very much in the eyes of the beholder. It involves a value judgement and can never be absolute. Yet paradoxically, modern society is demanding ever greater degrees of safety in the medicines it takes, to the extent that nothing short of the total absence of risk will be tolerated. Since 1960, and mainly as a result of the thalidomide tragedy, governmental regulation of testing and use of new medicines has grown apace throughout the world. It has derived impetus not only from the understandable wish of the public to seek protection, but also from the anxiety of bureaucrats and politicians not to be seen to have made mistakes. Both these concerns have been inflamed by the recognition of the media that all drugs make news and horror drugs make the best news of all. Prior to this time the physician and his cures enjoyed a relatively supportive public. It was true that quacks existed and were recognized as such but, in the main, people wanted to take medicines and expected them to do them good."@en ;
   schema:exampleOfWork <http://worldcat.org/entity/work/id/836679407> ;
   schema:genre "Electronic books"@en ;
   schema:inLanguage "en" ;
   schema:isSimilarTo <http://worldcat.org/entity/work/data/836679407#CreativeWork/> ;
   schema:name "Risk-Benefit Analysis in Drug Research : Proceedings of an International Symposium held at the University of Kent at Canterbury, England, 27 March 1980"@en ;
   schema:productID "840311790" ;
   schema:publication <http://www.worldcat.org/title/-/oclc/840311790#PublicationEvent/dordrecht_springer_netherlands_imprint_springer_1981> ;
   schema:publisher <http://experiment.worldcat.org/entity/work/data/836679407#Agent/springer> ; # Springer
   schema:publisher <http://experiment.worldcat.org/entity/work/data/836679407#Agent/imprint> ; # Imprint
   schema:publisher <http://experiment.worldcat.org/entity/work/data/836679407#Agent/springer_netherlands> ; # Springer Netherlands
   schema:url <http://dx.doi.org/10.1007/978-94-015-7132-6> ;
   schema:url <http://public.eblib.com/choice/PublicFullRecord.aspx?p=3106280> ;
   schema:workExample <http://worldcat.org/isbn/9789401571340> ;
   schema:workExample <http://dx.doi.org/10.1007/978-94-015-7132-6> ;
   schema:workExample <http://worldcat.org/isbn/9789401571326> ;
   wdrs:describedby <http://www.worldcat.org/title/-/oclc/840311790> ;
    .


Related Entities

<http://experiment.worldcat.org/entity/work/data/836679407#Agent/springer_netherlands> # Springer Netherlands
    a bgn:Agent ;
   schema:name "Springer Netherlands" ;
    .

<http://id.worldcat.org/fast/1014893> # Medicine
    a schema:Intangible ;
   schema:name "Medicine"@en ;
    .

<http://id.worldcat.org/fast/1153364> # Toxicology
    a schema:Intangible ;
   schema:name "Toxicology"@en ;
    .

<http://viaf.org/viaf/45641901> # J. F. Cavalla
    a schema:Person ;
   schema:familyName "Cavalla" ;
   schema:givenName "J. F." ;
   schema:name "J. F. Cavalla" ;
    .

<http://worldcat.org/entity/work/data/836679407#CreativeWork/>
    a schema:CreativeWork ;
   schema:description "Printed edition:" ;
   schema:isSimilarTo <http://www.worldcat.org/oclc/840311790> ; # Risk-Benefit Analysis in Drug Research : Proceedings of an International Symposium held at the University of Kent at Canterbury, England, 27 March 1980
    .

<http://worldcat.org/isbn/9789401571326>
    a schema:ProductModel ;
   schema:isbn "9401571325" ;
   schema:isbn "9789401571326" ;
    .

<http://worldcat.org/isbn/9789401571340>
    a schema:ProductModel ;
   schema:isbn "9401571341" ;
   schema:isbn "9789401571340" ;
    .

<http://www.worldcat.org/title/-/oclc/840311790>
    a genont:InformationResource, genont:ContentTypeGenericResource ;
   schema:about <http://www.worldcat.org/oclc/840311790> ; # Risk-Benefit Analysis in Drug Research : Proceedings of an International Symposium held at the University of Kent at Canterbury, England, 27 March 1980
   schema:dateModified "2018-11-07" ;
   void:inDataset <http://purl.oclc.org/dataset/WorldCat> ;
    .


Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.